Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!

Find a Clinical Research Study

31 - 40 of 207

CAMEO: Pediatric Crohn's Disease Outcomes Study

This two-phase study is being conducted to determine the reasons why some children with newly diagnosed Crohn's disease heal their bowel inflammation after one type of therapy and why others do not. To do this, the study team will ask to collect blood, stool and biopsy (tissue) samples from participants newly diagnosed with Crohn's disease to measure their inflammation markers and evaluate their genes (DNA). To determine how much a participant's bowels have healed, we will also compare colonoscopy and MRE results that occur as part of the participant's standard clinical care. 

Imaging Cognition and Neurodevelopment (ICAN)

The purpose of this research study is to examine relationships between brain and behavior development in toddlers with and without autism who have older siblings. 

You may qualify for our study if you or your child's healthcare provider has concerns regarding your toddler's development (communication, motor, behavior, or social concerns or developmental concerns). Toddlers must have older biological sibling(s) without autism.

Blood Sugar Stability in Individuals with Hyperinsulinism

The purpose of the study is to evaluate blood sugar levels and beta-cell function in adolescents and adult with KATP hyperinsulinism whom did not undergo pancreatectomy. We will perform oral glucose tolerance tests, glucose potentiated arginine tests, and evaluate blood sugars in home environment by using continuous glucose monitoring for 10 days.

DoSES

This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate. 

Shifting Perspectives

Researchers at CHOP are trying to improve outcomes in the treatment of adolescents with anorexia nervosa. Eligible families will receive Family Based Treatment for anorexia nervosa. Some adolescents with anorexia nervosa will also receive Cognitive Remediation Therapy (a treatment that increases flexible thinking). Both parents are required to participate and any siblings living at home are asked to come to the first four treatment sessions. Families will receive treatment for approximately 6 months and will be asked to complete number of assessments during treatment and at two time points after treatment ends.

Sleep Questionnaire for Infants with or at high-risk of Cerebral Palsy

The purpose of this research study is to look at whether or not a sleep questionnaire can be used on infants 3 to 24 months of age, with or at high-risk of having Cerebral Palsy. This questionnaire is currently being used on older children, so we will be looking at a younger age group.

CATC Biorepository

The Child and Adolescent Thyroid Consortium (CATC) Biorepository is a collaborative research program dedicated to studying thyroid cancers and other thyroid-related conditions. The goal of the CATC Biorepository is to address the unmet need of creating a well-annotated registry and bio specimen repository for patients with varying thyroid-related diagnoses. Collaborating clinicians and scientists are encouraged to use the specimens and infrastructure of the CATC Biorepository to make meaningful discoveries to help patients most at-risk.

ENERGY Study

The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.

You may be able to join the study if you are:

 

  •          18 years of age or older.
  •          Diagnosed with wAIHA for at least 3 months.
  •          Currently receiving treatment or have previously received treatment for wAIHA
  •          Have platelet counts of more than 30,000/ L and Hemoglobin less than 10 g/dL

 Other study requirements will apply.


Pages